Clovis Oncology (CLVS) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts CLVS Hot Sheet
Join SI Premium – FREE
Clovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($0.61), $0.05 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $36.82 million versus the consensus estimate of $41.12 million.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Syra Health Corp. (SYRA) Reports Q3 EPS of $0.02
- Tigress Financial Partners Reiterates Buy Rating on Jersey Mike's Subs (JMKE)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
